SCHEMBL16201634

SCHEMBL16201634

CC(C)c1c2n(c3ccsc13)CC(=O)N(C)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201672 0.78 THRB (0.30) —
SCHEMBL16201657 0.77 TSHR (0.34) —
SCHEMBL16201635 0.75 — —
SCHEMBL16201627 0.74 CHRNA7 (0.37) —
SCHEMBL16201638 0.72 CYP2D6 (0.30) —
SCHEMBL16201639 0.70 DRD2 (0.31) —
SCHEMBL16201641 0.65 FEN1 (0.36) —
SCHEMBL16201670 0.59 PDE4B (0.31) —
SCHEMBL16201668 0.57 CSNK2A2 (0.34) —
SCHEMBL19759274 0.56 ADORA1 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345905-B2 Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents NANJING ALLGEN PHARMA CO. LTD. (CN) 2016-05-24 — — US disclosed
US-20140322229-A1 HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS BETA PHARMA CANADA INC. (CA) 2014-10-30 — — US disclosed
Send feedback